
Sign up to save your podcasts
Or


This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
By Sam and Karine4.8
193193 ratings
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.

321 Listeners

504 Listeners

39 Listeners

121 Listeners

59 Listeners

3,374 Listeners

1,150 Listeners

187 Listeners

46 Listeners

518 Listeners

367 Listeners

53 Listeners

59 Listeners

51 Listeners

45 Listeners